心脏骤停昏迷复苏后的血压目标
BOXA随机双盲2×2析因试验纳入789例院外心脏骤停(推定心源性)复苏后昏迷成人,比较平均动脉压目标77 mmHg(高目标组393例)与63 mmHg(低目标组396例)。主要终点为90天内全因死亡或出院时脑功能分类(CPC)3或4分的复合终点,高目标组133例(34%)vs低目标组127例(32%)(HR 1.08;95%CI 0.84–1.37;P=0.56)。90天死亡高目标组122例(31%)vs低目标组114例(29%)(HR 1.13;95%CI 0.88–1.46),两组中位CPC均为1(四分位距1–5),中位改良Rankin量表评分均为1(四分位距0–6),中位蒙特利尔认知评估高目标组27分(四分位距24–29)vs低目标组26分(四分位距24–29),48小时神经元特异性烯醇化酶中位水平两组相似,不良事件百分比两组无显著差异。作者结论:77 mmHg或63 mmHg的平均动脉压目标在死亡或严重残疾/昏迷百分比上无显著差异。
要点
- 院外心脏骤停(推定心源性)复苏后昏迷成人,平均动脉压目标77 mmHg组90天死亡或CPC 3–4分复合终点133/393(34%),63 mmHg组127/396(32%),HR 1.08(95%CI 0.84–1.37;P=0.56)。
- 90天全因死亡高目标组122/393(31%)vs低目标组114/396(29%),HR 1.13(95%CI 0.88–1.46)。
- 两组90天中位CPC均为1(四分位距1–5),中位改良Rankin量表评分均为1(四分位距0–6)。
- 两组中位蒙特利尔认知评估高目标组27分(四分位距24–29)vs低目标组26分(四分位距24–29),48小时神经元特异性烯醇化酶中位水平相似。
- 两组不良事件百分比无显著差异。
适用人群与场景
- 院外心脏骤停后复苏、推定心源性病因、入住重症监护的昏迷成人,纳入本分析共789例(高目标组393例,低目标组396例)。
处置流程与药物剂量
- 平均动脉压目标随机分为77 mmHg(高目标组)或63 mmHg(低目标组),双盲实施。
研究设计与关键结果
- 双盲、随机、2×2析因试验:比较平均动脉压目标63 mmHg与77 mmHg,患者同时被分配至两个氧合目标之一(另文报告)。
- 主要终点为90天内全因死亡或出院时CPC 3或4分的复合终点:高目标组133/393(34%)vs低目标组127/396(32%),HR 1.08(95%CI 0.84–1.37;P=0.56)。
- 90天全因死亡:高目标组122/393(31%)vs低目标组114/396(29%),HR 1.13(95%CI 0.88–1.46)。
- 90天中位CPC两组均为1(四分位距1–5);中位改良Rankin量表评分高目标组1(四分位距0–6)vs低目标组1(四分位距0–6);中位蒙特利尔认知评估高目标组27分(四分位距24–29)vs低目标组26分(四分位距24–29)。
- 48小时神经元特异性烯醇化酶中位水平两组相似。
- 不良事件百分比两组无显著差异。
证据类型、等级与局限
- 证据类型:双盲、随机、2×2析因试验(BOX试验,ClinicalTrials.gov NCT03141099),由诺和诺德基金会资助。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于院外心脏骤停(推定心源性)复苏后昏迷的成人,将平均动脉压目标设为77 mmHg或63 mmHg,90天内死亡或严重残疾/昏迷的百分比无显著差异,支持两种目标均可采用。
- 两组90天中位CPC、改良Rankin量表评分、蒙特利尔认知评估及48小时神经元特异性烯醇化酶水平相似,不良事件百分比无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Evidence to support the choice of blood-pressure targets for the treatment of comatose survivors of out-of-hospital cardiac arrest who are receiving intensive care is limited.
METHODS: In a double-blind, randomized trial with a 2-by-2 factorial design, we evaluated a mean arterial blood-pressure target of 63 mm Hg as compared with 77 mm Hg in comatose adults who had been resuscitated after an out-of-hospital cardiac arrest of presumed cardiac cause; patients were also assigned to one of two oxygen targets (reported separately). The primary outcome was a composite of death from any cause or hospital discharge with a Cerebral Performance Category (CPC) of 3 or 4 within 90 days (range, 0 to 5, with higher categories indicating more severe disability; a category of 3 or 4 indicates severe disability or coma). Secondary outcomes included neuron-specific enolase levels at 48 hours, death from any cause, scores on the Montreal Cognitive Assessment (range, 0 to 30, with higher scores indicating better cognitive ability) and the modified Rankin scale (range, 0 to 6, with higher scores indicating greater disability) at 3 months, and the CPC at 3 months.
RESULTS: A total of 789 patients were included in the analysis (393 in the high-target group and 396 in the low-target group). A primary-outcome event occurred in 133 patients (34%) in the high-target group and in 127 patients (32%) in the low-target group (hazard ratio, 1.08; 95% confidence interval [CI], 0.84 to 1.37; P = 0.56). At 90 days, 122 patients (31%) in the high-target group and 114 patients (29%) in the low-target group had died (hazard ratio, 1.13; 95% CI, 0.88 to 1.46). The median CPC was 1 (interquartile range, 1 to 5) in both the high-target group and the low-target group; the corresponding median modified Rankin scale scores were 1 (interquartile range, 0 to 6) and 1 (interquartile range, 0 to 6), and the corresponding median Montreal Cognitive Assessment scores were 27 (interquartile range, 24 to 29) and 26 (interquartile range, 24 to 29). The median neuron-specific enolase level at 48 hours was also similar in the two groups. The percentages of patients with adverse events did not differ significantly between the groups.
CONCLUSIONS: Targeting a mean arterial blood pressure of 77 mm Hg or 63 mm Hg in patients who had been resuscitated from cardiac arrest did not result in significantly different percentages of patients dying or having severe disability or coma. (Funded by the Novo Nordisk Foundation; BOX ClinicalTrials.gov number, NCT03141099.).
参考来源
- Kjaergaard J, Møller JE, Schmidt H, et al. Blood-Pressure Targets in Comatose Survivors of Cardiac Arrest. N Engl J Med. 2022. PMID: 36027564. doi:10.1056/NEJMoa2208687
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。